NDAORALSUSPENSION
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
ATORVALIQ (atorvaliq) by Cmp Dev Llc is selective, competitive inhibitor of hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a to mevalonate, a precursor of sterols, including cholesterol. Approved for type 2 diabetes mellitus, heart failure. First approved in 2023.
Drug data last refreshed 13h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATORVALIQ is an oral suspension formulation of atorvastatin, a selective HMG-CoA reductase inhibitor that lowers cholesterol synthesis in the liver and increases LDL receptor uptake. It is indicated for type 2 diabetes mellitus and heart failure. The drug works by reducing plasma cholesterol and lipoprotein levels while enhancing hepatic LDL catabolism.
$0.161MPart D
Peak10.7 years to LOEProduct is at peak lifecycle with minimal Part D penetration (416 claims), suggesting opportunity for market expansion and field team growth.
Mechanism of Action
selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA…
Indications (2)
Worked on ATORVALIQ at Cmp Dev Llc? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.